Background/Aims: The term monoclonal gammopathy of renal significance (MGRS) was introduced in 2012 to emphasize kidney lesions in monoclonal gammopathy patients. Bortezomib-based chemotherapy has become the first-line treatment for MGRS. Objectives: The objective of this study was to investigate whether the strategy of combining chemotherapy with autologous stem cell transplantation (ASCT) could improve prognosis and decrease functional kidney impairment in patients with MGRS. Methods: We reported the case of a 44-year-old Asian patient who was diagnosed with MGRS and received 5 cycles of Velcade ® (a trade name for bortezomib), thalidomide, and dexamethasone therapy (VTD therapy), and subsequently underwent ASCT. In addition, we performed a literature review and summarized the latest advances in the characterization, treatment, and prognosis of MGRS. Results: The patient was diagnosed with light chain deposition disease by renal biopsy. After 5 cycles of VTD therapy, the patient had a very good partial response characterized by the resolution of M-protein (20.2% before treatment vs. 2.5% after treatment), remission of the level of serum free lambda (FLAM; over 80% decline), and normalization of the serum free light chain (sFLC) ratio (κ to λ). He also had a renal response characterized by a decreased serum creatinine level (1.61 vs. 1.34 mg/dL) and less severe proteinuria (6.77 g/24 h vs. 1.264 g/24 h) after chemotherapy. Importantly, after ASCT, the patient achieved a complete response (CR) characterized by a negative serum immunofixation electrophoresis (IFE) result and a dramatic decrement in FLAM (over 90%). Furthermore, 6 months after ASCT, the patient still remained in stable condition with a negative IFE result, normal sFLC ratio, and low level of serum creatinine (1.31 mg/dL) and proteinuria (0.339 g/24 h). In our retrospective literature analysis, we found that MGRS patient survival time and renal outcome had been markedly improved by current therapies due to the popularization of bortezomib-based chemotherapy and ASCT. Conclusions: The patient successfully achieved CR after VTD therapy followed by ASCT. However, this treatment is controversial, and a standard therapy recommendation for MGRS has not been established. Bortezomib-based chemotherapy combined with ASCT may have prospects for the treatment of MGRS, but the exact effects of ASCT remain unclear and should be thoroughly investigated.
Introduction
The clinical term monoclonal gammopathy of renal significance (MGRS) was first delineated by the International Kidney and Monoclonal Gammopathy Research Group in 2012 [1] . The definition of the group of hemato-nephrological entities as MGRS was intended to distinguish the disorders from monoclonal gammopathy of undetermined significance with respect to the risk of severe consequences in the kidney [2] . MGRS entities are characterized by pathogenesis driven by monoclonal immunoglobulin (MIg) secreted by small B cell and plasma cell clones in the absence of overt hematologic malignancy [3] . Patients with MGRS do not meet the criteria for overt multiple myeloma (MM) or systemic lymphoma [4] . Therefore, some kidney diseases that result from high-grade lymphoproliferative disorders or are independent of MIg, such as those resulting from drug toxicity or metabolic disorder, are excluded from MGRS [5] . Meanwhile, light chain deposition disease (LCDD), which includes only light chains (LCs), is the most common form of MGRS [6] .
Renal involvement caused by MGRS is severe and irreversible, and usually presents as atypical manifestations, such as hypertension, nephrotic syndrome, and renal insufficiency, that, if not successfully treated, evolve to end-stage renal disease (ESRD) [7] [8] [9] . In addition, MGRS is associated with high mortality, poor patient survival, and unsatisfactory renal outcomes with a high rate of recurrence even after triplet chemotherapy, autologous stem cell transplantation (ASCT), or renal transplantation [1] [2] [3] [4] [5] 8] . However, the prevalence of MGRS has consistently been underestimated as rare conditions. Currently, there is no established treatment for MGRS, and only limited clinical trials are available [10] . Herein, we report the case of a patient with IgA-λ subtype primary LCDD (PLCDD) and summarize the current status of the characterization, treatment, and prognosis of MGRS, with the aims of improving public awareness and shedding light on the treatment of MGRS.
Case Report
A 44-year-old man without any previous medical history came to our hospital with lower limb edema on March 22, 2017. Laboratory findings showed severe proteinuria (24-h urinary test: 6.077 g/24 h), hypoproteinemia (serum albumin: 2.59 g/dL), renal insufficiency (estimated glomerular filtration rate [eGFR]: 51 mL/min/1.73 m 2 , estimated with the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula), elevated serum creatinine (1.61 mg/dL), and mild anemia (hemoglobin: 10.7 g/dL). First, we strongly suspected nephrotic syndrome and immediately performed renal biopsy on the patient.
Light microscopy showed many hypocellular nodules in the mesangium with a large, pathologic glomerulus and severe expansion of the mesangial area. The biopsy was negative for Congo red staining. Immunofluorescence staining (IF) for λ-LCs was strongly positive along the glomerular capillary walls, tubular basement membrane (TBM), and tubulointerstitium, whereas κ-LCs and other antisera (i.e., IgG, IgG1, IgG2, IgG3, IgG4, IgM, IgA, C3, C4, and C1q) were all negative. Electron microscopy (EM) revealed the deposition of some electron-dense granules in the mesangial area, glomerular basement membrane (GBM), TBM, and interstitium (Fig. 1 ). Serum and urine immunofixation electrophoresis (IFE) suggested IgA-λ-related monoclonal gammopathy (Fig. 2) . IgA was detected at levels up to 13.4 g/L (normal range: 0.70-4.00 g/L) and the proportion of M-protein reached 21.8% of antibodies. Serum free kappa (FKAP) was detected at 19.5 mg/L (normal range: < 3.3-19.4 mg/L), whereas the serum free lambda (FLAM) was 150.4 mg/L (normal range: < 5.71-26.3 mg/L) and the ratio of FKAP to FLAM was 0.13 (normal range: < 0.26-1.65).
Bone marrow aspirate and biopsy showed an elevated proportion of plasma cells (under 5%) with no evidence of amyloid deposition. The bone marrow immunophenotyping assay revealed an abnormal monoclonal plasma cell phenotype (0.91% of all nucleated cells), characterized by the expression of CD138, CD45, and λ-LC and the absence of CD19, CD56, and The patient agreed to hyoid tissue biopsy and fat biopsy, both of which were negative (Fig. 2) . All imaging examinations (including skeletal survey, single-electron positron emission tomography, abdominal ultrasound, echocardiogram ultrasound, and cardiac magnetic resonance imaging) were normal. After combining these findings with the examination results, the final diagnosis was PLCDD.
To reduce LC burden and improve renal function, we commenced chemotherapy with Velcade ® (a trade name for bortezomib), thalidomide, and dexamethasone (VTD therapy) in May 2017. Thalidomide was orally administered at the initial therapeutic dose of 100 mg/day for 1 cycle, then adjusted to 75 mg/day for the remaining 4 cycles due to astriction. Dexamethasone (20 mg) was administered by subcutaneous injection on days 1, 2, 4, 5, 8, 9, 11, and 12. Velcade (2.5 mg) was administered by intravenous injection on days 1, 4, 8, and 11 ( Fig. 3) . A course of treatment lasted for 12 days, and the next course began at least 9 days later. After undergoing 5 cycles of the triple chemotherapy, the patient achieved a hematologic very good partial response (VGPR) characterized by the resolution of M-protein and normalization of the serum free light chain (sFLC) ratio (κ to λ). He also achieved a good renal response with lower serum creatinine and proteinuria than in the initial stage (Fig. 4) . Categorization of the hematologic response was adapted from the 2012 International The dynamic changes in various parameters at different treatment stages of this patient. A Changes in M-protein and IgA, both of which returned to normal after ASCT by serum IFE. B Changes in serum FLAM and the ratio of κ to λ as assessed by sFLC assay. C Changes in the levels of serum creatinine and eGFR (estimated by CKD-EPI formula). D Changes in the levels of 24-h proteinuria and serum albumin. E Changes in the levels of hemoglobin. After VTD therapy, 1 month after 5 cycles of VTD therapy; after ASCT, 1 week after ASCT; 6m later, 6 months after ASCT. Society of Amyloidosis criteria [11] and the renal response was assessed based on Kidney Disease: Improving Global Outcomes practice guidelines on glomerulonephritis [12] . After his good health was confirmed, the patient underwent ASCT in November 2017. Strikingly, after combined treatment with chemotherapy and ASCT, the patient achieved a complete response (CR) with a negative IFE result (no detectable M-protein or IgA) and marked remission of abnormal FLAM (over 90% decline compared to pre-treatment) as well as a normal sFLC ratio (Fig. 4) . However, an episode occurred 1 week after ASCT, in which some clinical parameters, including creatinine, eGFR (estimated by CKD-EPI formula), hemoglobin, albumin, and proteinuria, slightly deteriorated ( Fig. 4C-E) . The effects, which are common in posttransplant patients, may have been induced by the ASCT pre-treatment or treatment regimens. We then carried out follow-up observation of this patient. Thalidomide was discontinued when the patient had sustained his response for 3 months after ASCT, and only Velcade and dexamethasone were used in the course of chemotherapy. Six months after ASCT, the patient was still in stable condition with negative IFE findings and a normal κ-to-λ ratio. He also sustained relatively low serum creatinine and 24-h urine protein levels (Fig. 4) .
Review of the Literature
The term MGRS was introduced in 2012 to differentiate the included entities from monoclonal gammopathy of undetermined significance based on the presence of significant kidney lesions; in 2016, MGRS was classified into two groups by Sethi et al. [13] according to pathogenesis. One group is characterized by direct deposition of MIg in the kidney, whereas the other is subject to an indirect mechanism of MIg regulation and activation of the alternative complement pathway (Fig. 5) . However, while the designation MGRS helps highlight patients 
with renal diseases secondary to M-protein secretion by a premalignant clone, it is not a disease or diagnosis in itself [1, 2, 7, 8] .
A diagnosis of MGRS usually depends on the detection of MIg [14, 15] . Detection by IF and EM in the biopsy is indispensable. Immunoelectron microscopy may play an important role in some early cases with atypical pathologic characteristics. Several MIg assays are available in the clinic, including protein electrophoresis (PEP), IFE, and sFLC assays for serum and urine. The sensitivity of the sFLC assay to detect MGRS is higher than those of IFE and PEP [5, 16] . Recently, 2 new tests with higher sensitivities and specificities than sFLC assays have attracted attention. In the time-of-flight technique, a mass spectrometer can quickly and accurately detect M-proteins based on their mass-to-charge ratio. The other new technique, the analysis of urinary exosomes, is a useful tool for the study of cellular proteomics in the urinary tract. Urinary exosomes can be an excellent biomarker for renal response in LCDD [17] . However, the two techniques are not universally used in the clinic. Currently, no single test can provide all of the information necessary to the clinician. A thorough understanding of the capabilities and limitations of these tests will lead to better patient care.
In the past, some research suggested that it was unnecessary for patients with MGRS (except those with immunoglobulin LC amyloidosis [AL amyloidosis]) to receive systematic treatment due to low tumor burden [18] . However, increasing evidence indicates that aggressive therapy to control MIg in MGRS patients could improve renal function, delay the progression to ESRD, and reduce the rate of recurrence after renal transplantation [19] . If left untreated, nonmalignant B cell clones could lead to organ dysfunction and even deteriorate to MM as the disease progresses [20] . Therefore, active treatment for MGRS is essential for better prognosis. Generally, bortezomib-based chemotherapy is considered to be the firstline treatment strategy for MGRS due to the rapid and deep response [6, [21] [22] [23] . However, the benefit of the chemotherapy has been debated in the context of inconclusive bone marrow findings, especially when MIg is hardly detected in the serum or urine [24] ; the requirement for chemotherapy needs to be explored further. ASCT also represents an important treatment option for MGRS [25] [26] [27] . A controversial regimen of renal transplantation, which is associated with a high rate of recurrence and graft loss, has also been used [2, 5, 28, 29] . Therapeutic strategies for MGRS should focus on the eradication of pathogenic clonal cells. However, the development of a clone-specific approach presents the considerable challenge of choosing the most effective and clone-specific treatment with the safest adverse event profile, particularly when no B cell or plasma cell clone has been detected [4, 30] . Notably, the International Kidney and Monoclonal Gammopathy Research Group summarized specific therapeutic regimens according to MGRS disorder type. Options for LCDD treatment should take into account CKD stage and the availability of renal transplantation [31] .
Overall patient survival at 1 and 5 years (89 and 70%, respectively) is better than renal survival (67 and 17%, respectively) [1, 5, 18, 31, 32] . Prognostic factors for MGRS include age, serum creatinine in primary diagnosis, presence of plasma cell myeloma, and extrarenal LC deposition [7, 33] . Lower initial serum creatinine is recognized as the most valuable prognostic indicator of renal survival in multivariate analysis [7, [34] [35] [36] . Two retrospective studies by Nasr et al. [35] and Pozzi et al. [36] showed that earlier detection and the availability of newer therapeutic regimens (such as bortezomib-based chemotherapy and ASCT), respectively, could reduce mortality in patients and improve MGRS prognosis and outcomes (Table 1 ). In addition, in 2015, committee members of the National Amyloidosis Centre highlighted the relationship between hematologic response and renal outcome in patients with MGRS. The rate of native GFR loss among patients who did not achieve either CR or VGPR with chemotherapy was 6.5 mL/min/year, whereas the rate for those who achieved CR or VGPR improved by 6.1 mL/min/year. The data also demonstrated that ASCT could be successful, even in patients with a low GFR. Surprisingly, that research was the first to indicate that there
was no statistical difference in the renal survival of MGRS patients with or without nephroticrange proteinuria (> 3 g/24 h). Furthermore, renal survival was not influenced by the degree of bone marrow plasmacytosis [8] .
Discussion/Conclusion
The case we reported, of a patient diagnosed with IgA-λ PLCDD, was rare and notable. Typically, the ratio of κ to λ is 9: 1 in LCDD and abundant κ in the serum is associated with LCDD, whereas abundant λ is associated with AL amyloidosis [37] . In addition, IgG and IgM predominate in LCDD, and the percentage of LCDD associated with MM or lymphoproliferative disorders is over 80% [38, 39] . Thus, the probability of IgA-λ PLCDD is slim; the reason for its occurrence -genetics, environment, or ethnicity -is a puzzling question. Furthermore, the question of links between LC types (κ or λ) and the specific disorders of MGRS (such as LCDD) remains open. The mechanism driving IgA-λ PLCDD remains unknown.
In particular, the pathologic and morphologic features observed in the renal biopsy of this patient differed from the classic manifestations of LCDD. In classical LCDD, IF presents LCs as diffuse linear deposits along the GBM and TBM, and EM displays punctate, powdery, electron-dense deposits along the inner aspect of the GBM and the outer aspect of the TBM [9, 40, 41] . However, in this case, there was strong IF staining for λ-LCs along the glomerular capillary walls, TBM, and tubulointerstitium. Furthermore, the basement membrane was destroyed by EM, which could hardly distinguish the locations of the deposits. In addition, the subendothelial area was expanded with unknown material. Immunoelectron microscopy may have been needed to confirm the identity of the material and provide a definite diagnosis. Therefore, the diagnosis of LCDD in this patient required deliberation after the initial testing. These morphologic or histologic indices -glomerular density, number of tubules per glomerulus, tubular density, and fractal dimension of the tubular lumen -all have excellent correlation with the eGFR (estimated by CKD-EPI formula) [42] and are of utmost importance for patient prognosis.
Bortezomib can inhibit the progression of glomerulosclerosis and reduce proteinuria by interrupting the activation cascade of signaling pathways such as NF-κB that lead to rapid renal deterioration [43] . Thus, bortezomib-based chemotherapy had been regarded as the first-line treatment for MGRS. Beyond that, ASCT can provide a better prognosis for patients. Bortezomib is ideally suited for incorporation into induction therapy before ASCT to improve efficacy [44] . However, there is a lack of large-scale analysis of the curative effects of bortezomib-based chemotherapy combined with ASCT, which must be urgently addressed. Despite this, this newer therapy regimen has been adopted clinically with good response rates [45] [46] [47] [48] . Our patient accepted this regimen to achieve a better long-term outcome regardless of the financial burden. As expected, the regimen appeared successful. LCs are filtered by the glomeruli, bound by LC receptors on the surface of mesangial cells and vessel smooth muscle cells, reabsorbed in proximal tubules by receptor-mediated endocytosis, and degraded in tubular cells by lysosomal enzymes [8, 9, 39, 49] . Thus, the kidney is the principal target for LC deposition. However, LCs can also deposit in other tissues, including brain, heart, lung, liver, spleen, pancreas, muscle, pharynx, cervical lymph nodes, gastrointestinal tract, and nervous system, resulting in varying degrees of organ dysfunction that are rarely symptomatic [50] . In this patient, there were no signs of extrarenal organ involvement, which may improve his prognosis and outcome. His diagnosis of PLCDD that was not secondary to MM also improved his prognosis over patients with MM. In addition, the patient came to hospital early without serious kidney involvement, which protected him from the rapid loss of renal function. Due to the active treatment with chemotherapy and ASCT, he achieved hematologic CR and renal improvement. Moreover, he maintained hematologic CR for a relatively long time after ASCT. Thus, the successful treatment of the patient with bortezomibbased chemotherapy and ASCT may shed some light on the treatment of MGRS.
We reported this special case to enhance awareness of MGRS and describe options for a therapeutic regimen for MGRS. However, the case is complicated by some problems. The diagnosis of this patient with PLCDD was not clear and definite. The follow-up observation period was short (only 6 months), which may not completely reflect the curative effect of the treatment, and the renal survival and patient survival were not determined. The effect of the nature of the LC (IgA-λ) on the efficacy of the treatment or prognosis is unknown. In addition, it seems that ASCT actually worsened the clinical scenario (in terms of creatinine, eGFR, hemoglobin, albumin, and proteinuria). Although these changes were transient, they may have resulted from a posttransplant reaction. There is no indication that the ASCT was the reason for the improvement over the long-term.
MGRS is associated with a wide spectrum of kidney diseases, which are classified by the type, size, localization, and organization of deposited MIg in the absence of hematologic malignancy or other myeloma-defining events. Renal biopsy (especially for IF and EM) should be performed when MGRS is highly suspected. The treatment of MGRS is mainly based on chemotherapy that should be adapted to the lymphocytic or plasmacytic nature of the underlying clone, renal function based on CKD stage, and the presence or absence of extrarenal involvement. Bortezomib-based chemotherapy combined with ASCT may be a prospective treatment of MGRS, but the effects of ASCT remains unclear due to the complicated settings. In addition, the collateral effects of this therapy must be further investigated and taken into consideration. The therapeutic goal is to achieve at least VGPR and to stabilize or improve renal function.
Despite the rarity of the entities, randomized trials should be designed to identify the most beneficial and effective therapeutic approaches for affected patients. As MGRS is a heterogeneous and relatively rare entity, cooperation between nephrologists and hematologists in well-designed prospective collaborative studies is required to improve management. The development of methods to reduce the serious side effects of chemotherapy drugs and improve patient prognosis is a noteworthy challenge that should be discussed and investigated.
